For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.
It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.
This is an international site for TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
and is intended for Healthcare Professionals outside the US.
The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via www.novartisoncology.com/contact-novartis-oncology.jsp.
Below is a list of the countries that host a TAFINLAR website based on local label and in local language. They are intended for Healthcare Professionals (HCPs) only. If you are a HCP from one of the countries listed below, click on your country link to be redirected to your country TAFINLAR website.
Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.
During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.
Reach out to your Novartis representative with any questions related to Novartis products.